Keywords: Santaris Pharma, miRagen Thereapeutics, microRNA-targeted medicines, Cardiovascular disease

Santaris and miRagen in strategic alliance to develop microRNA-targeted medicines for cardiovascular disease

Article | 24 June 2010

Two developers of RNA-based therapeutics, Denmark-headquartered Santaris Pharma A/S and the USA’s miRagen Therapeutics, have formed a strategic ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Santaris Pharma

miRagen Therapeutics

Go to company listing